Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. 3,4 Dihydroxyphenylserine
2. 3,4 Threo Dops
3. 3,4-dihydroxyphenylserine
4. 3,4-threo-dops
5. Dl Threo 3,4 Dihydroxyphenylserine
6. Dl-threo-3,4-dihydroxyphenylserine
7. Droxidopa, (dl-tyr)-isomer
8. Erythro 3,4 Dihydroxyphenylserine
9. Erythro-3,4-dihydroxyphenylserine
10. Threo Dops
11. Threo-dops
1. 23651-95-8
2. L-dops
3. Dops
4. Northera
5. 3916-18-5
6. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid
7. Dl-threo-droxidopa
8. Dl-threo-3,4-dihydroxyphenylserine
9. Dl-threo-dops
10. Threo-dopaserine
11. L-threodops
12. L-threo-dops
13. Dl-threo-dihydroxyphenylserine
14. Threo-dihydroxyphenylserine
15. Sm 5688
16. Chebi:31524
17. L-dihydroxyphenylserine
18. Droxidopa (l-dops)
19. Serine, 3-(3,4-dihydroxyphenyl)-, Dl-threo-
20. L-threo-dihydroxyphenylserine
21. 24a0v01wks
22. J7a92w69l7
23. Dl-threo-beta-(3,4-dihydroxyphenyl)serine
24. Droxydopa
25. L-threo-3,4-dihydroxyphenylserine
26. Norethra
27. Droxidopa [latin]
28. Threo-beta,3-dihydroxy-dl-tyrosine
29. Einecs 223-480-5
30. Beta,3-dihydroxy-dl-tyrosine Threo-
31. 3,4-dihydroxyphenylserine
32. Brn 2852792
33. Droxidopum
34. L-tyrosine, Beta,3-dihydroxy-, Threo-
35. Unii-24a0v01wks
36. Dl-threo-3-(3,4-dihydroxyphenyl)serine
37. Droxidopa [usan:inn:jan]
38. Unii-j7a92w69l7
39. (2rs,3rs)-2-amino-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic Acid
40. L-threo 3,4-dihydroxyphenylserine
41. Northera (tn)
42. L-threo Dops
43. Dops (tn)
44. L-threo-3-(3,4-dihydroxyphenyl)serine
45. Dl-tyrosine, Beta,3-dihydroxy-, Threo-
46. Droxidopa [inn]
47. Droxidopa [jan]
48. Droxidopa [mi]
49. Threo-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid
50. Droxidopa [usan]
51. Dl-tyrosine, .beta.,3-dihydroxy-, Threo-
52. Droxidopa [vandf]
53. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic Acid
54. Droxidopa [mart.]
55. Droxidopa [who-dd]
56. 1-14-00-00685 (beilstein Handbook Reference)
57. 1260173-94-1
58. Schembl134299
59. Gtpl7391
60. Droxidopa (jp17/usan/inn)
61. Droxidopa [orange Book]
62. Chembl2103827
63. Dtxsid6046422
64. Droxidopa (l-dops,sm-5688)
65. Dtxsid201017236
66. Bcp06516
67. Zinc1482049
68. Bdbm50103611
69. Mfcd00799030
70. S3041
71. Sm5688
72. (betar)-beta,3-dihydroxy-l-tyrosine
73. L-dops, >=98% (hplc)
74. (2s,3r)-3,4-dihydroxy-phenylserine
75. Akos015889899
76. Ccg-222060
77. Db06262
78. Sm-5688
79. Ncgc00344531-04
80. As-61328
81. Hy-13458
82. L-tyrosine, Beta,3-dihydroxy-, (betar)-
83. D4235
84. L-tyrosine, Beta,3-dihydroxy-, (beta-r)-
85. Threo-3,4-dihydroxyphenylserine, L-
86. 3,4-dihydroxyphenylserine-threo, Dl-
87. Dl-threo- Beta -(3,4-dihydroxyphenyl)serine
88. (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine
89. D01277
90. D90266
91. Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-
92. Ab01566868_01
93. 916a185
94. A816824
95. Q907853
96. Sr-01000883755
97. Q-201050
98. Sr-01000883755-1
99. L-tyrosine, .beta.,3-dihydroxy-, (.beta.r)-
100. D-tyrosine, .beta.,3-dihydroxy-, (.beta.s)-rel-
101. 23651-95-8,1260173-94-1(hcl)
102. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid
103. (2s,3r)-3-(3,4-dihydroxyphenyl)-2-amino-3-hydroxypropanoic Acid
104. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic Acid
105. (2rs,3rs)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxy-propanoic Acid
106. (-)-(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid
Molecular Weight | 213.19 g/mol |
---|---|
Molecular Formula | C9H11NO5 |
XLogP3 | -3.2 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 3 |
Exact Mass | 213.06372245 g/mol |
Monoisotopic Mass | 213.06372245 g/mol |
Topological Polar Surface Area | 124 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 235 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Northera |
PubMed Health | Droxidopa (Oral route) |
Drug Classes | Adrenergic, Vasopressor |
Drug Label | NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is... |
Active Ingredient | Droxidopa |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 300mg; 100mg |
Market Status | Prescription |
Company | Lundbeck Na |
2 of 2 | |
---|---|
Drug Name | Northera |
PubMed Health | Droxidopa (Oral route) |
Drug Classes | Adrenergic, Vasopressor |
Drug Label | NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is... |
Active Ingredient | Droxidopa |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 300mg; 100mg |
Market Status | Prescription |
Company | Lundbeck Na |
For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.
Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
C - Cardiovascular system
C01 - Cardiac therapy
C01C - Cardiac stimulants excl. cardiac glycosides
C01CA - Adrenergic and dopaminergic agents
C01CA27 - Droxidopa
Absorption
Oral bioavailability is 90%.
Route of Elimination
Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.
Droxidopa is metabolized by aromatic L-amino acid decarboxylase.
2-3 hours.
Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-20
Pay. Date : 2019-01-31
DMF Number : 33459
Submission : 2019-01-04
Status : Active
Type : II
NDC Package Code : 76278-1120
Start Marketing Date : 2016-11-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34389
Submission : 2019-12-31
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-02-08
Pay. Date : 2017-12-06
DMF Number : 32264
Submission : 2017-11-24
Status : Active
Type : II
NDC Package Code : 53069-1060
Start Marketing Date : 2014-02-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-01-12
Pay. Date : 2017-10-10
DMF Number : 31514
Submission : 2017-03-28
Status : Active
Type : II
Date of Issue : 2019-07-26
Valid Till : 2022-08-08
Written Confirmation Number : WC-0383
Address of the Firm :
NDC Package Code : 69766-032
Start Marketing Date : 2017-03-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-11-15
Pay. Date : 2018-08-22
DMF Number : 33089
Submission : 2018-09-18
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-02-25
Pay. Date : 2019-12-31
DMF Number : 34258
Submission : 2019-12-20
Status : Active
Type : II
NDC Package Code : 65085-0071
Start Marketing Date : 2023-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-11-16
Pay. Date : 2017-10-17
DMF Number : 32032
Submission : 2017-10-06
Status : Active
Type : II
Date of Issue : 2022-06-07
Valid Till : 2025-06-16
Written Confirmation Number : WC-0049
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20556
Submission : 2007-05-23
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-03-20
Pay. Date : 2019-01-31
DMF Number : 33459
Submission : 2019-01-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-01-10
Pay. Date : 2020-11-25
DMF Number : 35368
Submission : 2020-11-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-02-02
Pay. Date : 2017-11-08
DMF Number : 32184
Submission : 2017-12-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-11-16
Pay. Date : 2017-10-17
DMF Number : 32032
Submission : 2017-10-06
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-01-12
Pay. Date : 2017-10-10
DMF Number : 31514
Submission : 2017-03-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-02-25
Pay. Date : 2019-12-31
DMF Number : 34258
Submission : 2019-12-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-02-08
Pay. Date : 2017-12-06
DMF Number : 32264
Submission : 2017-11-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20556
Submission : 2007-05-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34389
Submission : 2019-12-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-15
Pay. Date : 2018-08-22
DMF Number : 33089
Submission : 2018-09-18
Status : Active
Type : II
Registration Number : 218MF10452
Registrant's Address : Rejiawan, Dashiba, Nan an, Chongqing China
Initial Date of Registration : 2006-04-27
Latest Date of Registration : 2007-02-13
Registration Number : 222MF10282
Registrant's Address : No. 8 Jiangqiao Road, Nan an District Chongqing China
Initial Date of Registration : 2010-12-24
Latest Date of Registration : 2010-12-24
Registration Number : 218MF10680
Registrant's Address : Renjiawan, Dashiba, Nan an Chongqing 40006, China
Initial Date of Registration : 2006-08-11
Latest Date of Registration : 2006-08-11
Registration Number : 221MF10115
Registrant's Address : 25, Barangongdan-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea
Initial Date of Registration : 2009-06-16
Latest Date of Registration : 2009-06-16
Registration Number : 228MF10144
Registrant's Address : 25, Barangongdan-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea
Initial Date of Registration : 2016-08-03
Latest Date of Registration : 2016-08-03
Date of Issue : 2022-06-07
Valid Till : 2025-06-16
Written Confirmation Number : WC-0049
Address of the Firm : Block 21, Dabhasa, Padra Taluka, Vadodara-391 440
Date of Issue : 2019-07-26
Valid Till : 2022-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Sy. No.455/A, 455/AA, 455/E & 455/EE Chandampet Village Shankarampet Mandal Meda...
Registrant Name : Polaris AI Pharma Co., Ltd.
Registration Date : 2018-08-14
Registration Number : 20180814-211-J-252
Manufacturer Name : Estec Pharma Co., Ltd. @ [Pr...
Manufacturer Address : 25 Balan Industrial Complex Road, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, 34 Block 10...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-049
Start Marketing Date : 2016-07-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42973-237
Start Marketing Date : 2017-12-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76278-1120
Start Marketing Date : 2016-11-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 70966-0006
Start Marketing Date : 2018-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69766-032
Start Marketing Date : 2017-03-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65085-0071
Start Marketing Date : 2023-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 53069-1060
Start Marketing Date : 2014-02-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38217-0030
Start Marketing Date : 2014-02-18
End Marketing Date : 2030-12-31
Dosage Form (Strength) : POWDER (40kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?